Ann: Race releases complete cardio-protection data & video, page-72

penicillin took 20+ years to develop since discovery.

Race landed on cardio protect and FTO the last couple of years. Maybe timeline expectations are a little different. Even Keytruda took years to develop and Covid is an example of the absolute limit of development and that took over a year.

Currently trading below cost price for historical development. If AML went through to approval and cardio protect and FTO failed, what would Race be worth?

Why was penicillin so groundbreaking and still around today? It solved a problem.

Cardiotoxicity is a problem for two reasons, causes irreversible heart damage and caps lifetime dosing. So increase survival and reduction of heart damage, if given the choice would you prefer standard chemo or Zantrene? If the later would be the overwhelming consensus there is value, it is simply economics Supply v. Demand.

So why is the market not moving, it does not do DD on biotech potential. NEU is a recent example, price moved a just before approval and only massive rerate after. Who were the winners the LT holding since sub $2 or those buying on market at $9+ post approval.

My view for biotechs that the market relies on announced data. Once validated market will price in. With any speculation there is an increased Risk v Reward scenario that can play out.

There is still risk of failure so DYOR not advice.